Wisp Launches Into Fertility, Expanding Access to Reproductive Care

Wisp is Now Serving Women Through Every Stage of their Sexual Wellness and Reproductive Care Lifespan

Wisp, the fastest growing sexual and reproductive telehealth provider in the U.S, today announced a new fertility vertical consisting of several products and services to help birthers navigate getting pregnant. Fertility is an integral part of a women’s reproductive health journey, as 1 in 5 women of childbearing age struggle to conceive. This launch is Wisp’s latest move in making healthcare affordable and accessible for women, who on average spend upwards of $40,000 on in vitro fertilization (IVF).

“As a company, we’re obsessed with listening to our patients and building new solutions that fit their needs, and launching fertility is addressing two major pain points our patients face. A recent survey we conducted found that 70% of our patients were interested in more education on fertility and products that help those trying to conceive,” said Monica Cepak, CEO of Wisp. “By providing at-home testing and medications that can help women conceive and potentially have them avoid costly IVF treatments, we are providing a valuable service to women at this stage in their life. By helping women through this pre-IVF phase or before other in-clinic assisted reproductive technology is needed, we are offering accessible options for what can often be a confusing and stressful time for women trying to conceive.”

To meet the growing demands of today’s consumers looking for assistance with getting pregnant, Wisp has entered into strategic partnerships with Proov, the creator of a suite of at-home fertility-related hormone tests, and PherDal, creators of the first and only sterile, at-home insemination kit. Wisp will begin selling Proov’s ovarian reserve and hormone testing, His/Hers fertility kits, and pregnancy tests. Additionally, Wisp patients will have exclusive telehealth access to PherDal’s FDA cleared, 100% sterile at-home insemination kit to members. In the near future, Wisp will also launch fertility consultations, at-home blood draws, and additional prescription medications.

“Fertility is a very personal journey for each patient. Wisp is working to make it easier to access the tools, treatments, and information you need to feel empowered and knowledgeable about your options,” said Dr. Jillian LoPiano, Wisp’s Chief Health Officer, MD, MPH, FACOG.

Wisp offers patients the treatments they need, when they need it, with no hassle, judgment, and no insurance required. Through private online consultations, patients receive over-the-counter treatments and prescriptions in just three hours on average - either via same-day pharmacy pickup or free discreet delivery in all 50 states. To learn more about Wisp, visit www.hellowisp.com.

ABOUT WISP:

Wisp is a women’s health company on a mission to make sexual and reproductive healthcare more inclusive, cost-effective, and accessible. Available in all 50 states, Wisp provides discreet treatments online with a comprehensive selection of products and telehealth services, including prescription medication, OTC prevention, at-home testing and more. Wisp is a growing and profitable company and is majority-owned by WELL. To learn more, please visit hellowisp.com or follow @hellowisp on Facebook, Instagram, TikTok and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240612275905/en/